Translation, cross-cultural adaptation and validation of the Chinese version of irritable bowel syndrome severity scoring system
Open Access
- 7 May 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1779402
Abstract
Objective: Given that the Irritable Bowel Syndrome Severity Scoring System (IBS-SSS) is widely utilized in IBS-related clinical research but lacks an officially approved Chinese version (IBS-SSS-C), which has impeded its application in Chinese research contexts. This study aims to translate and cross-culturally adapt the IBS-SSS into a Chinese version, and validate its key properties, thereby developing a reliable and officially recognized tool for assessing IBS severity among the Chinese population. Methods: We obtained translation permission for the IBS-SSS from the Rome Foundation, and translated and cross-culturally adapted it into a Chinese version according to the official guideline. Validation was performed as clinical trials assessing responsiveness to change ( n = 95), test–retest reliability ( n = 35) and the floor-ceiling effects ( n = 95) of IBS-SSS-C. We assessed the IBS-SSS-C score’s responsiveness to change using adequate relief (AR) as an anchor. Results: Through forward and backward translation, and cross-cultural adaption, the IBS-SSS-C was developed and approved for use by the Rome Foundation. A significance difference in the absolute change of the IBS-SSS-C total score before and after treatment was found in the AR responder and non-responder groups ( p = 0.001). This trend also emerged for the items abdominal pain severity ( p = 0.032), abdominal pain frequency ( p = 0.001), and bowel habit satisfaction ( p = 0.036). There was good test–retest reliability ( r = 0.72) for the IBS-SSS-C total score, and a moderate to good correlation ( r = 0.41–0.81) for each of its items. No floor or ceiling effect was found in either IBS-SSS-C or any of its item. Conclusion: Our findings indicate that the IBS-SSS-C appears to be a reliable and appropriate instrument for IBS outcome assessment in the Chinese population; nevertheless, further validation in larger-scale, multi-center studies is required.Keywords
This publication has 31 references indexed in Scilit:
- Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized TrialGastroenterology, 2020
- Post-marketing Re-evaluation of Tongxiening Granules (痛泻宁颗粒) in Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Multi-center, Randomized, Double-Blind, Double-Dummy and Positive Control TrialChinese Journal of Integrative Medicine, 2019
- The effect of Xiang-Sha-Liu-Jun-Zi tang (XSLJZT) on irritable bowel syndrome: A randomized, double-blind, placebo-controlled trialJournal of Ethnopharmacology, 2019
- Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018Gastroenterology, 2019
- Are personalized tongxie formula based on diagnostic analyses more effective in reducing IBS symptoms?—A randomized controlled trialComplementary Therapies in Medicine, 2018
- Validation of the Japanese version of the Rome II modular questionnaire and irritable bowel syndrome severity indexJournal of Gastroenterology, 2006
- Clinical trial guidelines for pharmacological treatment of irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 2003
- AGA technical review on irritable bowel syndromeGastroenterology, 2002
- The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progressAlimentary Pharmacology & Therapeutics, 1997
- Individual-patient monitoring in clinical practice: are available health status surveys adequate?Quality of Life Research, 1995